antiprolif
cethynylnucleosid
nucleosid
nucleosid
glycosyl
b
r
c
focus
nucleosid
librari
construct
around
cethynyldribofuranos
sugar
scaffold
coupl
various
modifi
purin
nucleobas
result
nucleosid
probe
abil
inhibit
tumor
cell
prolifer
well
activ
panel
relev
human
virus
substitut
purin
nucleosid
found
weakli
activ
sever
nucleosid
elicit
potent
antiprolif
activ
activ
spectrum
evalu
tumor
cell
line
panel
indic
activ
sever
solid
tumor
deriv
cell
line
analog
equip
base
evalu
metastat
breast
tumor
xenograft
model
inhibit
tumor
growth
reduc
format
lung
metastas
reveal
bli
analysi
dideazanucleosid
analog
show
interest
activ
hcmv
result
highlight
potenti
advantag
recombin
known
sugar
nucleobas
motif
librari
design
strategi
discov
novel
antivir
antitumor
agent
nucleosid
analog
cornerston
antivir
therapi
notabl
success
treatment
hiv
hepat
c
viru
infect
furthermor
nucleosid
analog
also
found
widespread
use
oncolog
approv
deriv
activ
variou
form
lymphoma
focus
screen
librari
compris
nucleosid
analog
surround
singl
modifi
dribofuranos
moieti
could
viabl
strategi
discov
attract
hit
aforement
diseas
area
evidenc
number
recent
public
paper
rather
underrepres
cethynylribofuranos
motif
use
sugar
scaffold
construct
small
librari
nucleosid
analog
previou
report
mainli
focus
pyrimidin
like
nucleobas
moieti
structur
resembl
cytidin
analog
ecyd
fig
emerg
promis
deriv
initi
discoveri
cethynyl
nucleosid
ecyd
evalu
clinic
trial
new
antitumor
agent
recent
attract
renew
interest
combin
therapi
eg
carboplatin
part
duplex
drug
link
purin
counterpart
hand
exemplifi
cethynyladenosin
analog
eado
receiv
littl
attent
motiv
us
combin
peculiar
cethynyl
sugar
element
differ
purin
nucleobas
build
focus
librari
previous
report
seri
purin
analog
fig
cethynyladenosin
eado
consid
interest
biolog
properti
report
nucleosid
compris
arylpurin
eg
fig
base
recent
coin
privileg
scaffold
part
natur
nucleosid
antibiot
tubercidin
contribut
investig
effect
combin
base
moieti
cethynylribofuranos
moieti
target
nucleosid
analog
prepar
glycosyl
use
either
acet
scheme
benzoat
scheme
protect
sugar
precursor
reaction
condit
depend
type
nucleobas
purin
vs
analog
synthesi
purin
analog
accomplish
via
suzuki
reaction
nucleosid
appropri
phenylboron
acid
final
compound
obtain
deprotect
nh
meoh
scheme
synthesi
scheme
use
aforement
sugar
precursor
provid
desir
glycosyl
product
low
yield
cumbersom
purif
procedur
switch
benzoat
protect
sugar
deriv
improv
coupl
yield
isol
glycosyl
product
contamin
residu
glycosyl
donor
degrad
product
tent
assign
base
h
nmr
data
shown
treatment
crude
intermedi
nh
meoh
nh
oh
elev
c
temperatur
caus
decomposit
therefor
altern
protocol
introduc
group
employ
nucleophil
displac
sodium
azid
effici
deliv
correspond
azid
deriv
gener
could
obtain
pure
form
due
mark
differ
polar
induc
predomin
tetrazolo
tautom
stauding
reduct
furnish
correspond
deriv
deprotect
afford
final
compound
dehalogen
intermedi
subject
img
exchang
use
knochel
iprmgcllicl
magnesi
intermedi
quench
aqueou
acid
give
good
yield
convers
realiz
describ
introduct
moieti
achiev
via
aqueou
suzuki
reaction
remark
suzuki
reaction
substrat
gave
significantli
lower
yield
reaction
start
materi
similar
glycosyl
strategi
follow
synthet
trifluoromethyl
analog
upper
line
scheme
treat
commerci
ii
tmsotf
reflux
b
substitut
phenylboron
acid
k
co
pd
ph
p
toluen
c
c
n
nh
meoh
bodi
text
purin
number
use
nucleosid
analog
howev
experiment
section
iupac
nomenclatur
pyrrolo
pyrimidin
number
appli
order
allow
facil
comparison
assign
nmr
data
provid
experiment
section
pyrrolo
pyrimidin
number
indic
select
deriv
ital
bracket
pyrimidin
langloi
reagent
sodium
trifluoromethanesulfin
presenc
j
cross
peak
c
ghmbc
spectrum
compound
see
support
inform
allow
ascertain
glycosyl
howev
larg
coupl
constant
j
hz
observ
inconsist
cf
group
attach
led
us
assign
structur
trifluoromethyl
compound
prepar
use
langloi
reagent
regioisom
substitut
heterocycl
could
obtain
known
iodid
subsequ
nboc
protect
trifluoromethyl
use
ruppert
reagent
nboc
protect
group
lost
reaction
comparison
h
nmr
spectra
regioisom
see
support
inform
led
confirm
thu
also
substitut
isom
note
recent
patent
applic
describ
regioisom
regiochem
assign
opposit
conclus
substitut
heterocycl
use
synthet
desir
product
follow
reaction
sequenc
obtain
ethynyl
substitut
analog
scheme
sonogashira
reaction
envis
avoid
select
issu
cethynyl
group
group
protect
tm
group
glycosyl
introduct
ethynyl
chain
transform
employ
reaction
sequenc
describ
synthesi
cethyl
analog
start
catalyt
hydrogen
give
rise
subject
glycosyl
condit
glycosyl
product
directli
use
elabor
describ
synthesi
pyrrolo
pyridin
nucleosid
analog
scheme
commerci
avail
pyridin
halogen
appropri
halosuccinimid
glycosyl
product
obtain
use
condit
counterpart
lewi
acidmedi
glycosyl
type
heterocycl
report
gener
nucleobaseanion
glycosyl
acidcatalyz
fusion
employ
ensur
transform
regioand
stereochemistri
ascertain
c
ghmbc
noesi
experi
see
support
inform
deprotect
nh
meoh
gave
final
product
deiodin
img
exchang
gave
good
yield
deprotect
furnish
expect
introduct
azido
group
eg
problemat
due
higher
electron
densiti
pyrrolo
pyridin
system
respect
pyrrolo
pyrimidin
system
desir
product
could
detect
reaction
nan
c
gradual
increas
temperatur
c
higher
led
degrad
issu
led
us
introduc
azido
group
glycosyl
step
scheme
glycosyl
employ
condit
chloridesubstitut
heterocycl
first
attempt
afford
two
product
ident
isom
assign
stauding
reduct
scheme
facilit
purif
c
ghmbc
spectrum
show
markedli
differ
crosspeak
pattern
heterocycl
moieti
see
support
inform
synthesi
iodosubstitut
accomplish
use
condit
tent
isom
could
observ
tlc
analysi
isol
formal
character
intermedi
afford
deprotect
satur
nh
meoh
desir
nucleosid
ribofuranosylpurin
nucleosid
fail
display
inhibitori
activ
cell
line
prolifer
remark
cethynyltubercidin
well
analog
inhibit
prolifer
differ
tumor
cell
line
nanomolar
ic
valu
chloro
bromo
analog
show
highest
antiprolif
activ
irrespect
cell
line
studi
unsubstitut
deriv
show
similar
activ
eado
interestingli
observ
structureantiprolif
activ
relationship
small
subset
significantli
differ
observ
correspond
ribofuranos
deriv
substitut
analog
found
weakli
inhibit
tumor
cell
prolifer
contrast
potent
activ
observ
correspond
similarli
analog
show
weak
antiprolif
activ
also
contrast
activ
observ
correspond
ribofuranos
analog
satur
ethynyl
substitu
result
two
order
magnitud
lower
ic
analog
gave
submicromolar
activ
correspond
isom
complet
devoid
activ
possibl
due
prefer
antiorient
purin
ring
activ
investig
import
synthet
pyrrolo
pyridin
analog
interestingli
analog
elicit
antiprolif
effect
notabl
cem
cell
line
chlorid
analog
except
chlorid
seri
antiprolif
activ
correl
halogen
size
br
cl
h
analog
significantli
less
activ
relat
approxim
case
iodosubstitut
analog
display
potent
antiprolif
activ
especi
cell
line
explor
potenti
new
nucleosid
analog
potent
analog
select
test
cell
line
panel
tabl
summar
gi
valu
repres
cell
line
full
assay
data
well
mean
gi
graph
provid
support
inform
potent
growth
inhibitori
activ
observ
less
activ
activ
spectrum
former
analog
found
broad
especi
pronounc
leukemia
cell
line
observ
eg
clofarabin
gi
valu
sever
solid
tumor
cell
line
eg
nm
addit
analog
evalu
potenti
inhibit
cell
prolifer
three
differ
endotheli
cell
type
agent
capabl
modifi
tumor
vasculatur
either
antiangiogen
vasculardisrupt
action
interest
antitumor
therapi
singl
agent
combin
chemotherapeut
drug
disrupt
vascular
network
solid
tumor
may
induc
collaps
depriv
oxygen
nutrient
nucleosid
analog
found
potent
inhibit
prolifer
three
endotheli
cell
type
studi
halogen
deriv
cl
br
potent
unfortun
analog
also
significantli
inhibit
prolifer
helfibroblast
encourag
strong
vitro
antiprolif
activ
analog
variou
tumor
cell
line
scheme
reagent
condit
appropri
nhalosuccinimid
dmf
tabl
analog
select
vivo
evalu
antitumor
activ
metastat
breast
cancer
xenograft
mous
model
employ
cell
express
firefli
luciferas
antitumor
activ
assess
measur
bli
signal
fig
panel
tumor
volum
panel
b
cell
orthotop
engraft
scid
mice
treatment
commenc
tumor
palpabl
day
compound
inject
intratumor
mgkg
time
week
two
consecut
week
tumor
growth
significantli
retard
start
day
ie
four
inject
measur
bioluminesc
radianc
panel
reduc
tumor
growth
also
obviou
tumor
size
measur
use
digit
calip
panel
b
day
mice
sacrif
tumor
remov
macroscop
examin
panel
b
averag
control
tumor
weight
mg
versu
mg
treatment
group
analyz
effect
lung
metastasi
mice
cover
black
paper
imag
shield
primari
tumor
interestingli
total
metastasi
burden
lung
significantli
lower
treat
group
day
versu
vehicl
control
group
panel
c
indic
nucleosid
analog
exhibit
antitumor
activ
also
reduc
breast
cancer
metastasi
secondari
organ
analog
either
show
antivir
activ
highest
concentr
test
mm
assay
panel
relev
virus
see
experiment
section
activ
accompani
signific
toxic
host
cell
make
deriv
nonspecif
data
shown
analog
combin
antivir
activ
accept
select
indic
result
summar
tabl
tabl
eado
show
activ
vaccinia
viru
tabl
although
also
potent
inhibit
hel
cell
line
prolifer
tabl
activ
vaccinia
viru
also
found
howev
gener
inhibit
cell
prolifer
see
also
tabl
promis
antivir
activ
found
compound
exhibit
potent
activ
human
cytomegaloviru
hcmv
reason
select
index
halogensubstitut
deriv
br
display
elev
cytotox
therefor
nonselect
appar
observ
activ
specif
halogen
bear
compound
parent
compound
without
halogen
inact
furthermor
chang
amino
group
mimick
natur
adenin
detriment
activ
compar
develop
nucleosid
librari
around
cethynylribofuranos
moieti
combin
sever
purin
nucleobas
bear
substitu
previous
found
confer
biolog
activ
combin
sugar
motif
purin
nucleosid
analog
devoid
antiprolif
antivir
activ
analog
well
trifluoromethyl
deriv
unsubstitut
analog
found
significantli
inhibit
growth
three
tumor
cell
line
spectrum
activ
thoroughli
investig
except
assay
panel
also
reveal
nanomolar
activ
sever
solid
tumor
deriv
cell
line
remov
nitrogen
introduct
substitut
particularli
halogen
deriv
shown
lead
significantli
potent
antiprolif
nucleosid
modifi
deriv
previous
report
addit
analog
potent
inhibit
prolifer
endotheli
cell
type
could
particularli
interest
treatment
solid
tumor
proofofconcept
analog
investig
metastat
breast
cancer
xenograft
mous
model
deriv
inhibit
tumor
growth
well
metastasi
assess
mean
bli
howev
also
potent
inhibit
vitro
prolifer
helfibroblast
requir
optim
improv
select
sever
analog
prepar
found
potent
inhibitor
human
cytomegaloviru
hcmv
vitro
particularli
analog
requir
evalu
conclus
result
present
paper
showcas
util
screen
focus
nucleosid
librari
antivir
well
antiprolif
activ
mean
find
novel
hit
elabor
reagent
solvent
obtain
standard
commerci
sourc
analyt
grade
unless
otherwis
specifi
use
receiv
prepar
accord
literatur
procedur
halogen
heterocycl
pyrimidin
prepar
commerci
avail
pyrimidin
employ
literatur
condit
moistur
sensit
reaction
carri
argon
atmospher
reaction
carri
ambient
temperatur
unless
otherwis
indic
analyt
tlc
perform
macherynagel
precoat
aluminum
plate
visual
uv
follow
stain
basic
aq
kmno
sulfur
acidanisaldehyd
spray
column
chromatographi
perform
use
davisil
mm
reveleri
grace
autom
flash
unit
employ
prepack
silica
column
exact
mass
measur
perform
water
lct
premier
time
flight
tof
mass
spectromet
equip
standard
electrospray
esi
modular
interfac
sampl
infus
mecnwat
formic
acid
mixtur
mlmin
nmr
spectra
record
varian
mercuri
mhz
spectromet
chemic
shift
given
ppm
spectra
referenc
residu
solvent
peak
coupl
constant
given
hz
f
nmr
signal
referenc
cdcl
dmsod
lock
reson
frequenc
accord
iupac
referenc
cfcl
set
ppm
glycosyl
correct
stereochemistri
b
correct
regiochemistri
purin
number
glycosyl
product
ascertain
mean
nmr
techniqu
noesi
antivir
activ
express
ec
valu
mm
repres
concentr
test
compound
necessari
reduc
viralinduc
cytopathogen
b
mcc
minim
cytotox
concentr
repres
concentr
test
compound
abl
caus
microscop
detect
alter
normal
cell
morpholog
c
cc
repres
concentr
mm
test
compound
reduc
cell
hel
prolifer
determin
coulter
counter
c
ghmbc
respect
either
protect
deprotect
deriv
depend
peak
resolut
melt
point
determin
apparatu
uncorrect
puriti
assess
mean
analyt
lcm
employ
either
water
allianc
xe
separ
modul
use
phenomenex
luna
reversedphas
column
mm
mm
gradient
system
hcooh
obtain
final
compound
puriti
assay
analyt
hplc
uv
unless
otherwis
indic
flamedri
ml
roundbottom
flask
equip
stir
bar
ad
argon
purin
nucleosid
deriv
mmol
eq
correspond
boron
acid
eq
anhydr
k
co
eq
pd
ph
p
eq
flask
evacu
refil
argon
three
time
anhydr
degass
toluen
ml
mlmmol
sm
ad
mixtur
stir
approxim
min
heat
c
tlc
monitor
show
full
convers
start
materi
mixtur
allow
cool
room
temperatur
filter
evapor
till
dryness
residu
purifi
column
chromatographi
acetonedcm
ester
protect
nucleosid
eq
dissolv
nh
meoh
stir
ambient
temperatur
tlc
show
full
convers
gener
overnight
mixtur
evapor
dryness
residu
purifi
column
chromatographi
typic
meohdcm
flamedri
round
bottom
flask
equip
stir
bar
ad
appropri
heterocycl
eq
argon
anhydr
mecn
mlmmol
sm
ad
follow
bsa
eq
result
suspens
stir
ambient
temperatur
approxim
min
clear
solut
obtain
glycosyl
donor
eq
ad
one
portion
immedi
follow
tmsotf
eq
result
solut
stir
ambient
temperatur
anoth
min
transfer
preheat
oil
bath
c
heat
continu
tlc
analysi
show
full
consumpt
start
materi
mixtur
cool
ambient
temperatur
ea
ad
mixtur
pour
sat
aq
nahco
solut
layer
separ
water
layer
extract
twice
ea
organ
layer
combin
dri
na
filter
evapor
till
dryness
residu
purifi
column
chromatographi
eahexan
appropri
chloronucleosid
eq
dissolv
dmf
mlmmol
nan
eq
ad
mixtur
stir
c
min
mixtur
cool
ambient
temperatur
pour
halfsatur
aq
nahco
solut
ea
layer
separ
water
layer
extract
two
time
ea
organ
layer
combin
dri
na
filter
evapor
till
dryness
residu
purifi
column
chromatographi
eahexan
yield
protect
azidonucleosid
appropri
azidonucleosid
eq
dissolv
thf
mlmmol
pme
solut
thf
eq
ad
mixtur
stir
ambient
temperatur
tlc
analysi
show
full
convers
start
materi
gener
min
h
next
solut
evapor
till
dryness
subsequ
redissolv
mecn
mlmmol
solut
ad
aq
hoac
solut
eq
mixtur
heat
preheat
oil
bath
c
next
mixtur
cool
ambient
temperatur
pour
sat
aq
nahco
solut
dcm
ad
layer
separ
water
layer
extract
two
time
dcm
organ
layer
combin
dri
na
filter
evapor
till
dryness
purif
column
chromatographi
eahexan
gave
rise
protect
nucleosid
aminopurin
prepar
accord
literatur
procedur
spectral
data
accord
literatur
valu
g
mmol
eq
suspend
hmd
ml
mlmmol
sm
catalyt
amount
nh
ad
mixtur
reflux
overnight
cool
ambient
temperatur
result
solut
care
evapor
till
dryness
result
oil
dri
high
vacuum
h
anhydr
ml
ml
mmol
sm
ad
dissolv
silyl
heterocycl
g
mmol
eq
ad
via
syring
immedi
follow
tmsotf
ml
mmol
eq
result
solut
subsequ
reflux
approxim
min
cool
ambient
temperatur
mixtur
pour
sat
aq
nahco
dcm
ad
layer
separ
water
layer
extract
twice
dcm
organ
layer
combin
dri
na
filter
evapor
till
dryness
residu
purifi
column
chromatographi
acetonedcm
give
g
mmol
white
foam
yield
remark
correct
stereoand
regiochemistri
ascertain
transform
small
amount
cethynyladenosin
compar
nmr
data
literatur
refer
confirm
correct
structur
prepar
accord
gener
procedur
c
g
mmol
gave
rise
g
white
foam
contain
impur
therefor
immedi
use
next
step
prepar
accord
gener
procedur
c
g
mmol
gave
rise
g
yellow
foam
contain
impur
therefor
immedi
use
next
step
prepar
accord
gener
procedur
c
g
mmol
gave
rise
g
yellow
foam
contain
impur
therefor
immedi
use
next
step
prepar
accord
gener
procedur
g
mmol
gave
rise
g
mmol
white
solid
yield
purif
eahexan
prepar
accord
gener
procedur
g
mmol
gave
rise
g
mmol
slightli
yellow
foam
yield
purif
eahexan
pyrimidin
prepar
employ
sequenc
gener
procedur
c
e
g
mmol
gave
rise
g
mmol
white
foam
yield
g
mmol
eq
coevapor
anhydr
toluen
ml
three
time
result
foam
dissolv
anhydr
toluen
ml
mlmmol
sm
argon
cool
c
stir
temperatur
min
iprmgcllicl
thf
ml
mmol
eq
ad
dropwis
help
syring
pump
mlmin
complet
addit
mixtur
stir
c
cool
remov
aq
sat
nh
cl
ad
mixtur
dilut
ea
addit
water
ad
layer
separ
water
layer
extract
twice
ea
organ
layer
combin
dri
na
filter
evapor
residu
purifi
column
chromatographi
et
otoluen
give
g
mmol
white
foam
yield
g
mmol
eq
acid
g
mmol
eq
na
co
g
mmol
eq
pd
oac
g
mmol
eq
tppt
g
mmol
eq
ad
ml
roundbottom
flask
equip
stir
bar
next
flask
evacu
refil
argon
procedur
repeat
three
time
total
next
degass
mecn
ml
h
ml
ad
solid
argon
min
stir
mixtur
heat
c
preheat
oil
bath
start
materi
fulli
consum
min
mixtur
cool
ambient
temperatur
neutral
aq
hcl
mixtur
evapor
till
dryness
resuspend
meoh
evapor
three
time
next
mixtur
adsorb
onto
celit
meoh
elut
short
silica
pad
cm
meohdcm
liquid
evapor
vacuo
purifi
column
chromatographi
meohdcm
give
g
mmol
white
solid
yield
melt
point
c
triobenzoyl
bdribofuranosyl
pyrrolo
pyrimidin
triobenzoylbd
ribofuranosyl
pyrrolo
pyrimidin
triobenzoylb
dribofuranosyl
pyrrolo
pyrimidin
triobenzoylb
dribofuranosyl
pyrrolo
pyrimidin
triobenzoylb
dribofuranosyl
pyrrolo
pyrimidin
triobenzoyl
bdribofuranosyl
pyrrolo
triobenzoylbd
ribofuranosyl
pyrrolo
pyrimidin
cethynylbd
ribofuranosyl
pyrrolo
pyrimidin
suspens
g
mmol
eq
sodiumtrifluoromethylsulfin
g
mmol
eq
mixtur
dcmwater
ml
ratio
concentr
total
cool
ice
bath
c
stir
temperatur
min
aq
tbuooh
ml
mmol
eq
ad
dropwis
mlmin
addit
complet
ice
bath
remov
vigor
stir
continu
day
mixtur
partit
sat
aq
nahco
solut
dcm
layer
separ
water
layer
extract
twice
dcm
combin
organ
layer
dri
na
filter
evapor
till
dryness
purif
column
chromatographi
eahexan
gave
g
mmol
white
solid
yield
f
nmr
mhz
cdcl
c
nmr
mhz
cdcl
q
j
hz
q
j
hz
cf
q
j
hz
spectral
data
accord
literatur
valu
g
mmol
eq
suspend
anhydr
ml
mlmmol
sm
dmap
g
mmol
eq
ad
follow
dbu
ml
mmol
eq
next
boc
ml
mmol
eq
ad
dropwis
result
mixtur
stir
ambient
temperatur
overnight
next
mixtur
ad
sat
aq
nh
cl
eawat
ad
layer
separ
water
layer
extract
twice
ea
organ
layer
combin
dri
na
filter
evapor
till
dryness
residu
purifi
column
chromatographi
eahexan
yield
g
mmol
slightli
yellow
solid
yield
flame
dri
cultur
flask
equip
stir
bar
ad
argon
g
mmol
eq
kf
g
mmol
eq
cui
g
mmol
eq
g
mmol
eq
flask
evacu
refil
argon
three
time
anhydr
dmso
ml
mlmmol
sm
ad
follow
b
ome
tmscf
mixtur
submerg
preheat
oil
bath
c
mixtur
allow
cool
ambient
temperatur
partit
water
et
layer
separ
water
layer
extract
et
combin
organ
layer
wash
dilut
aq
ammonia
solut
follow
brine
dri
na
filter
evapor
till
dryness
residu
purifi
column
chromatographi
acetonedcm
result
product
found
suffici
pure
use
next
step
glycosyl
howev
slight
amount
remain
iodoheterocycl
thu
without
boc
protect
group
could
effici
remov
employ
sonogashira
reaction
pd
ph
p
cl
eq
cui
eq
et
n
mlmmol
dmf
mlmmol
eq
reaction
time
obtain
slightli
yellow
solid
pyrimidin
prepar
accord
gener
procedur
c
g
mmol
gave
rise
g
slightli
yellow
foam
contain
impur
therefor
immedi
use
next
step
gener
procedur
gener
procedur
e
flamedri
ml
round
bottom
flask
argon
ad
g
mmol
eq
cui
g
mmol
eq
pd
ph
p
cl
g
mmol
eq
flask
evacu
refil
argon
three
time
anhydr
degass
dmf
ml
mlmmol
sm
ad
follow
degass
et
n
ml
mlmmol
sm
ethynyltrimethylsilan
ml
mmol
eq
mixtur
stir
ambient
temperatur
overnight
subsequ
evapor
till
dryness
residu
purifi
column
chromatographi
eahexan
three
sequenc
give
g
mmol
yellowish
foam
yield
g
mmol
dissolv
ea
ml
mlmmol
sm
nitrogen
atmospher
catalyt
amount
pdc
ad
reaction
mixtur
stir
hydrogen
atmospher
balloon
approxim
h
mixtur
flush
nitrogen
filter
short
pad
celit
filtrat
evapor
till
dryness
purifi
column
chromatographi
eahexan
give
mmol
white
foam
yield
caution
reaction
employ
larg
amount
sodium
azid
combin
mild
acid
well
substanti
heat
therefor
consid
explos
hn
accid
occur
perform
reaction
run
howev
reaction
scale
never
exceed
mmol
heterocycl
sm
addit
protect
mean
blast
shield
close
fume
hood
strongli
recommend
pyridin
g
mmol
eq
dissolv
dmf
ml
mlmmol
sm
nh
cl
g
mmol
eq
ad
follow
nan
g
mmol
eq
mixtur
heat
c
behind
blast
shield
h
mixtur
allow
cool
ambient
temperatur
dilut
ea
pour
halfsat
aq
nahco
solut
layer
separ
water
layer
wash
twice
ea
organ
layer
combin
dri
na
filter
evapor
till
dryness
residu
purifi
column
chromatographi
eapet
give
g
mmol
white
solid
yield
melt
point
c
decompos
caution
see
note
regard
addit
safeti
measur
perform
reaction
g
mmol
eq
nh
cl
g
mmol
eq
suspend
dmf
ml
mlmmol
sm
nan
g
mmol
eq
ad
result
mixtur
heat
c
h
behind
blast
shield
cool
ambient
temperatur
mixtur
dilut
ea
pour
halfsatur
aq
nahco
solut
layer
separ
water
layer
extract
twice
ea
organ
layer
combin
dri
na
filter
evapor
residu
purifi
column
chromatographi
eahexan
give
g
mmol
grey
powder
yield
melt
point
c
decompos
g
mmol
eq
dissolv
dmf
ml
ml
mmol
sm
ni
g
mmol
eq
ad
mixtur
stir
dark
overnight
icecold
water
ml
mlmmol
sm
ad
result
precipit
filter
solid
wash
four
addit
time
icecold
water
ml
mlmmol
sm
solid
collect
dri
high
vacuum
give
g
mmol
yellow
solid
yield
melt
point
c
decompos
hela
cem
cell
assay
perform
microtit
plate
well
ad
tumor
cell
given
amount
test
compound
cell
allow
prolifer
h
murin
leukemia
cell
h
human
lymphocyt
cem
human
cervix
carcinoma
hela
cell
c
humidifi
co
control
atmospher
end
incub
period
cell
count
coulter
counter
anali
belgium
ic
inhibitori
concentr
defin
concentr
compound
inhibit
cell
prolifer
evalu
assay
protocol
concern
tumor
cell
panel
evalu
found
follow
refer
endotheli
cell
ec
primari
human
umbil
vein
endotheli
cell
huvec
human
dermal
microvascular
endotheli
cell
hmvecd
purchas
lonza
vervier
belgium
human
microvascular
endotheli
cell
line
obtain
center
diseas
control
prevent
cdc
atalanta
ga
usa
ec
seed
gelatinco
plate
cellswel
ec
growth
medium
lonza
overnight
incub
dilut
compound
ad
ec
allow
prolifer
four
day
presenc
compound
trypsin
count
mean
coulter
counter
determin
ic
valu
femal
sever
combin
immunodefici
scid
mice
use
age
week
anim
bred
anim
facil
rega
institut
medic
research
ku
leuven
belgium
lung
metastat
cell
line
clone
kind
gift
prof
massagu
e
cell
suspend
matrigel
bd
bioscienc
pb
orthotop
engraft
expos
left
fourth
inguin
mammari
fat
pad
anesthet
scid
mice
tumor
palpabl
day
inject
intratumor
mgkg
pb
contain
dmso
time
week
week
control
mice
receiv
pb
dmso
growth
luciferaseposit
cell
quantifi
ivi
spectrum
imag
system
calip
life
scienc
hopkinton
usa
imag
mice
anesthet
inject
subcutan
mgkg
dluciferin
perkinelm
imag
acquir
everi
min
plateau
radianc
valu
photon
sec
retain
lung
metastasi
determin
shield
primari
tumor
black
paper
tumor
size
measur
use
digit
calip
calcul
follow
formula
tumor
volum
mm
x
b
longest
diamet
b
shortest
diamet
ethic
statement
studi
done
complianc
ethic
guidelin
anim
welfar
ku
leuven
compound
evalu
follow
virus
herp
simplex
viru
type
strain
ko
thymidin
kinasedefici
tk
ko
strain
resist
acv
acv
r
herp
simplex
viru
type
strain
lyon
g
varicellazost
viru
vzv
strain
oka
tk
vzv
strain
human
cytomegaloviru
hcmv
strain
davi
vaccinia
viru
lederl
strain
respiratori
syncyti
viru
rsv
strain
long
vesicular
stomat
viru
vsv
coxsacki
parainfluenza
influenza
viru
subtyp
influenza
viru
b
sindbi
punta
toro
antivir
assay
base
inhibit
virusinduc
cytopath
plaqu
format
human
embryon
lung
hel
fibroblast
african
green
monkey
cell
vero
human
epitheli
cell
hela
madindarbi
canin
kidney
cell
mdck
confluent
cell
cultur
microtit
plate
inocul
ccid
viru
ccid
viru
dose
infect
cell
cultur
plaqu
form
unit
pfu
vzv
presenc
vari
concentr
test
compound
viral
cytopath
plaqu
format
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
ec
compound
concentr
requir
reduc
virusinduc
cytopathogen
viral
plaqu
format
cytotox
concentr
express
mcc
minim
cytotox
concentr
compound
concentr
requir
afford
microscop
visibl
alter
cell
morpholog
assay
involv
hcmv
vzv
perform
describ
literatur
short
antivir
assay
base
inhibit
virusinduc
cytopath
plaqu
format
human
embryon
lung
hel
fibroblast
confluent
cell
cultur
microtit
plate
inocul
ccid
hcmv
ccid
viru
dose
infect
cell
cultur
plaqu
form
unit
pfu
vzv
h
residu
viru
remov
cell
cultur
incub
presenc
vari
concentr
test
compound
viral
cytopath
hcmv
plaqu
format
vzv
record
soon
reach
complet
control
virusinfect
cell
cultur
untreat
control
antivir
activ
express
ec
concentr
requir
reduc
virusinduc
cytopath
viral
plaqu
format
declar
interest
none
